A Phase 1b/2, Multicenter, Open-label Study of ACP-196 in Subjects With Recurrent Glioblastoma Multiforme (GBM)
Acerta Pharma BV
Acerta Pharma BV
Dana-Farber Cancer Institute
University of Chicago
BeOne Medicines
Dana-Farber Cancer Institute
Acerta Pharma BV
Incyte Corporation
AstraZeneca
Ohio State University Comprehensive Cancer Center
Fred Hutchinson Cancer Center
Acerta Pharma BV
University of California, San Diego
M.D. Anderson Cancer Center
University of Utah
Mayo Clinic
MingSight Pharmaceuticals, Inc
Aprea Therapeutics
Oncternal Therapeutics, Inc
Genmab
Columbia University
Altor BioScience
M.D. Anderson Cancer Center
Celgene
Sumitomo Pharma America, Inc.
OHSU Knight Cancer Institute
AbbVie
Asana BioSciences
Bristol-Myers Squibb
Massachusetts General Hospital
Dana-Farber Cancer Institute
Atara Biotherapeutics
Precision BioSciences, Inc.
Molecular Templates, Inc.
Fred Hutchinson Cancer Center
Alexion Pharmaceuticals, Inc.
National Institutes of Health Clinical Center (CC)
National Cancer Institute (NCI)
Celgene
Northwestern University
Aptevo Therapeutics
Novartis
Masonic Cancer Center, University of Minnesota
National Institutes of Health Clinical Center (CC)
Mayo Clinic
Mayo Clinic
Mayo Clinic
Fred Hutchinson Cancer Center
M.D. Anderson Cancer Center
M.D. Anderson Cancer Center
Fred Hutchinson Cancer Center